---
layout: default
title: Palbociclib
parent: Model Prediction Only (L5)
nav_order: 1008
evidence_level: L5
indication_count: 4
---

# Palbociclib
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **4** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Palbociclib: From Breast Cancer to Hyperthyroidism

## One-Sentence Summary

Palbociclib is an oral CDK4/6 inhibitor. The Evidence Pack does not list its approved indication, but the supplied literature describes it as a treatment for hormone receptor-positive breast cancer.
The TxGNN model predicts it may be effective for **hyperthyroidism**, but there are **0 clinical trials** and **0 publications** supporting this direction, so it is a model prediction only.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not stated in the license data. The supplied literature describes use in HR+/HER2- breast cancer. |
| Predicted New Indication | Hyperthyroidism |
| TxGNN Prediction Score | 99.44% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 12 license records (2 distinct NDAs: NDA212436, NDA207103) |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, palbociclib is a CDK4/6 inhibitor whose efficacy in breast cancer is established in the literature. No mechanistic reason for it to work in hyperthyroidism can be drawn from the available data.

The score of 99.44% is a model output only. The Evidence Pack finds no mechanistic link between CDK4/6 inhibition and thyroid hormone excess. It also found no trials or publications for this indication. Until an independent biological rationale is established, the prediction should be treated as a hypothesis to test, not as supported evidence.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## US Market Information

| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---------|------|------|-----------|
| NDA212436 | Ibrance | Film-coated tablet | Pfizer Laboratories Div Pfizer Inc; U.S. Pharmaceuticals |
| NDA207103 | Ibrance | Capsule | Pfizer Laboratories Div Pfizer Inc; U.S. Pharmaceuticals |

Both forms are oral.

## Cytotoxicity

The drug is treated as antineoplastic because the literature describes it as a breast cancer therapy. The DrugBank category data was not supplied.

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (CDK4/6 inhibitor) |
| Myelosuppression Risk | Neutropenia and bone marrow suppression are described in the supplied literature. Please refer to the package insert for the grading. |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | CBC with differential (based on the myelosuppression signal). Please refer to the package insert for the full list. |
| Handling Protection | Please refer to the package insert warnings and precautions |

## Safety Considerations

Package insert warnings and contraindications were not available in the Evidence Pack, and no drug interaction records were found. Please refer to the package insert for safety information.

The supplied literature highlights these signals for CDK4/6 inhibitors as a class, palbociclib included:
- **Myelosuppression** (neutropenia), which is especially relevant if the drug were used in a non-oncology population.
- **Thromboembolic events**, reported in pharmacovigilance analyses and real-world studies (e.g., PMIDs 35300061, 36794339).
- **Interstitial lung disease**, a less common but potentially severe adverse event (PMID 37994878).

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The hyperthyroidism prediction rests on a model score alone (L5). There are no trials, no publications, no supported mechanism, and the original mechanism of action is missing. The class safety profile (myelosuppression, thromboembolism) also makes it a poor fit for a benign, treatable endocrine condition.

**To proceed, the following is needed:**
- Mechanism of action data (from DrugBank) and the approved indication text from the package insert
- Package insert warnings and contraindications, which are blocking for safety screening
- A biological rationale linking CDK4/6 inhibition to thyroid hormone excess, plus any preclinical evidence
- Consideration of the rank 2 prediction, **rheumatoid arthritis** (L4). It has preclinical work on synovial fibroblast proliferation and one case report of improvement in a breast cancer patient. It is a stronger research question than hyperthyroidism, though it still has no clinical trials.

*This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any use.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

